home / stock / esaly / esaly quote
Last: | $61.51 |
---|---|
Change Percent: | -1.37% |
Open: | $62.35 |
Close: | $61.51 |
High: | $63.29 |
Low: | $61 |
Volume: | 331,859 |
Last Trade Date Time: | 01/30/2023 03:39:52 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$61.51 | $62.35 | $61.51 | $63.29 | $61 | 331,859 | 01-30-2023 |
$62.835 | $62.29 | $62.835 | $63.35 | $62.29 | 94,525 | 01-27-2023 |
$63.97 | $64.3 | $63.97 | $64.72 | $63.3 | 44,236 | 01-26-2023 |
$64.345 | $64.025 | $64.345 | $64.69 | $63.97 | 44,032 | 01-25-2023 |
$63.5 | $63.52 | $63.5 | $63.82 | $62.44 | 22,761 | 01-24-2023 |
$65.49 | $63.43 | $65.49 | $66 | $63.27 | 12,536 | 01-23-2023 |
$65.95 | $65.385 | $65.95 | $66.19 | $65.385 | 14,592 | 01-20-2023 |
$65.1 | $63.68 | $65.1 | $65.2 | $63.5 | 8,881 | 01-19-2023 |
$64.61 | $64.865 | $64.61 | $64.9 | $64.25 | 6,589 | 01-18-2023 |
$63.92 | $63.04 | $63.92 | $65.03 | $63.04 | 15,353 | 01-17-2023 |
$63.65 | $63.16 | $63.65 | $63.66 | $63.15 | 12,579 | 01-16-2023 |
$63.65 | $63.16 | $63.65 | $63.66 | $63.15 | 12,579 | 01-13-2023 |
$63.15 | $62.92 | $63.15 | $63.15 | $61.85 | 27,532 | 01-12-2023 |
$64.08 | $63.54 | $64.08 | $64.08 | $62.5 | 37,909 | 01-11-2023 |
$65.6 | $65 | $65.6 | $65.6 | $64.772 | 35,042 | 01-10-2023 |
$63.7 | $68 | $63.7 | $68.25 | $63.7 | 70,581 | 01-09-2023 |
$64.2 | $62.96 | $64.2 | $68.85 | $61.07 | 314,515 | 01-06-2023 |
$61.67 | $60.97 | $61.67 | $61.67 | $60.4 | 27,447 | 01-05-2023 |
$62.57 | $63.78 | $62.57 | $63.98 | $62.52 | 22,923 | 01-04-2023 |
$66.35 | $67.004 | $66.35 | $67.004 | $65.96 | 14,469 | 01-03-2023 |
News, Short Squeeze, Breakout and More Instantly...
Eisai Co. Ltd. ADR Company Name:
ESALY Stock Symbol:
OTCMKTS Market:
Nine months after the U.S. launch of Eisai Limited (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Leqembi, the first drug sho...
Biogen Inc (NASDAQ:BIIB) and Eisai Co Ltd (OTC:ESALF) (OTC:ESALY) faced a setback as the much-anticipated Oral Explanation...
The FDA expects to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee to discuss Eli Lilly and Company...